SOR101 represents an opportunity to manage ICI mediated colitis (IMC) with an oral, gut-restricted treatment approach.

Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of a wide variety of malignancies and are being used in treatment regimens for several indications. IMC is often cited as a common adverse event in these patients and can lead to treatment discontinuation (temporarily or permanently).

• SOR101 is an anti-TNFa Vorabody that has been shown to reach inflamed intestinal mucosa and engage its target after oral dosing in humans
• Oral SOR101 therapy could address colitis associated with immune checkpoint inhibitor therapies
• Incidence can be as high as 32%, especially in the case of patients receiving multiple ICIs